by Pau Turon Dols, Vice-President of Research and Development, B. Braun Surgical, S.A.U.
The challenges to successfully develop a new medical device or a new drug are numerous. Some of them are related to funding, others to the complexity of the clinical need and the technical feasibility of the development by itself or the regulatory framework. However, the most challenging aspect is always the human team behind the project and their attitude towards life. This seminar deals with all those factors and how they interlink in the context of a multinational firm as B. Braun, particularly focused on the Center of Excellence for Closure Technologies located in Rubí (Barcelona) that holds the worldwide responsibility to develop new approaches for wound closure after surgery.
Pau Turon is Vice-President of Research and Development in B. Braun Group in Spain. He obtained a doctorate in Chemistry (UPC-2019) and a doctorate in Business Administration (UAB-2015) and degrees in Chemistry (UB), Economics (UAB) and Business Administration (UAB). He is author of more than 60 scientific articles and 10 patents. Through his career of 30 years in B. Braun, a biomedical multinational firm, he has developed and successfully launched to the market more than 30 products, medicinal substances (i.e. antibiotic and anesthetic drugs) and medical devices focused on closure technologies of a surgical wound (i.e. sutures, hernia meshes, tissue glues, hemostats and vacuum therapy devices). Currently, he is pushing several basic research lines (i.e. nanoparticles for fighting bacterial biofilms and hydroxyapatite catalyst to recycle carbon dioxide).
Hosted by Anna Roig, Nanoparticles & Nanocomposites Group, ICMAB, CSIC